Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Innovent Biologics's Enterprise Value is HK$55,461 Mil.
Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1,300 Mil. Therefore, Innovent Biologics's EV-to-EBIT ratio for today is -42.65.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Innovent Biologics's Enterprise Value is HK$55,461 Mil.
Innovent Biologics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-871 Mil. Therefore, Innovent Biologics's EV-to-EBITDA ratio for today is -63.71.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Innovent Biologics's Enterprise Value is HK$55,461 Mil.
Innovent Biologics's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$8,088 Mil. Therefore, Innovent Biologics's EV-to-Revenue ratio for today is 6.86.
Innovent Biologics Enterprise Value Historical Data
The historical data trend for Innovent Biologics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Innovent Biologics's Enterprise Value
For the Biotechnology subindustry, Innovent Biologics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Enterprise Value falls into.
Innovent Biologics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Innovent Biologics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (HKSE:01801) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Innovent Biologics's current Enterprise Value is HK$55,461 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-1,300 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Innovent Biologics's current Enterprise Value is HK$55,461 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-871 Mil.
Innovent Biologics's current Enterprise Value is HK$55,461 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$8,088 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Innovent Biologics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01801 has been successfully added to your 